Two-Drug attack tested for Tough-to-Treat Hodgkin's lymphoma
NCT ID NCT02940301
Summary
This study is testing whether combining two drugs, ibrutinib and nivolumab, can help control classical Hodgkin's lymphoma that has returned or hasn't responded to previous treatments. The trial involves 18 adults who have already had at least one prior therapy. Researchers want to see if this combination can shrink tumors completely and keep the cancer from progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Winship Cancer Center of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.